Arrowhead Pharmaceuticals (ARWR) Income from Discontinued Operations (2010 - 2013)
Arrowhead Pharmaceuticals (ARWR) posted Income from Discontinued Operations of 336.0 for Q1 2013, down 1766.67% on a QoQ basis from 18.0 in Q4 2012, and up 30.43% year-over-year from 257.6 in Q1 2012.
Arrowhead Pharmaceuticals (ARWR) Income from Discontinued Operations (2010 - 2013) Analysis & Trends
Arrowhead Pharmaceuticals' Income from Discontinued Operations history runs 4 years deep, the most recent figure standing at 336.0 for Q1 2013.
- Quarterly Income from Discontinued Operations rose 30.43% year-over-year to 336.0 in Q1 2013, while the trailing twelve-month figure through Sep 2013 was 354.0 (down 337.04% YoY) and the FY2013 annual result came in at 354.0, down 342.5% from the prior year.
- Income from Discontinued Operations was 336.0 for Q1 2013 at Arrowhead Pharmaceuticals, down from 18.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 1574994.0 in Q4 2010 and bottomed at 768160.0 in Q2 2010.
- A 4-year average of 28586.42 and a median of 349.0 in 2011 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2011 — Income from Discontinued Operations slumped 100.01% — and 2012, when it jumped 100.98%.
- Arrowhead Pharmaceuticals' Income from Discontinued Operations stood at 1574994.0 in 2010, then plunged by 100.01% to 220.0 in 2011, then jumped by 91.82% to 18.0 in 2012, then tumbled by 1766.67% to 336.0 in 2013.
- Business Quant data shows ARWR's Income from Discontinued Operations at 336.0 in Q1 2013, 18.0 in Q4 2012, and 55.0 in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Arrowhead Pharmaceuticals | 12.26 Bn | 10.47 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | -336.00 |
| Dec 31, 2012 | -18.00 |
| Sep 30, 2012 | -55.00 |
| Jun 30, 2012 | 677.00 |
| Mar 31, 2012 | -483.00 |
| Dec 31, 2011 | -220.00 |
| Sep 30, 2011 | -362.00 |
| Jun 30, 2011 | -68,742.00 |
| Mar 31, 2011 | -132,495.00 |
| Dec 31, 2010 | 1.57 Mn |
| Sep 30, 2010 | -261,763.00 |
| Jun 30, 2010 | -768,160.00 |